Antibe Therapeutics (TSX:ATE) Days Sales Outstanding : 0.00 (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Antibe Therapeutics Days Sales Outstanding?

Antibe Therapeutics's average Accounts Receivable for the three months ended in Dec. 2023 was C$0.00 Mil. Antibe Therapeutics's Revenue for the three months ended in Dec. 2023 was C$0.00 Mil.

The historical rank and industry rank for Antibe Therapeutics's Days Sales Outstanding or its related term are showing as below:

During the past 12 years, Antibe Therapeutics's highest Days Sales Outstanding was 99.43. The lowest was 38.05. And the median was 40.34.

TSX:ATE's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 72.665
* Ranked among companies with meaningful Days Sales Outstanding only.

Antibe Therapeutics's Days Sales Outstanding stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

Antibe Therapeutics Days Sales Outstanding Historical Data

The historical data trend for Antibe Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antibe Therapeutics Days Sales Outstanding Chart

Antibe Therapeutics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Days Sales Outstanding

Get a 7-Day Free Trial

38.05

40.29

Antibe Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Antibe Therapeutics's Days Sales Outstanding

For the Biotechnology subindustry, Antibe Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Antibe Therapeutics's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antibe Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Antibe Therapeutics's Days Sales Outstanding falls into.

Antibe Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Antibe Therapeutics's Days Sales Outstanding for the fiscal year that ended in Mar. 2023 is calculated as

	Days Sales Outstanding (A: Mar. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Mar. 2022 )	+	Accounts Receivable (A: Mar. 2023 ))	/	count )	/	Revenue (A: Mar. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365
=	0					/	0	*	365
=	N/A

Antibe Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365 / 4
=	0					/	0	*	365 / 4
=	N/A

Antibe Therapeutics (TSX:ATE) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Antibe Therapeutics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Antibe Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Antibe Therapeutics (TSX:ATE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antibe Therapeutics Inc (TSX:ATE) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

ATBPF:USA

Address

15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2

Website

https://www.antibethera.com

Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.

Executives

Daniel Marcel Legault	Senior Officer
Alain Wilson	Senior Officer
John Lawrence Wallace	Director, Director or Senior Officer of 10% Security Holder, Senior Officer
Nicolas Bourgeois	Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Scott Wilson Curtis	Senior Officer

Antibe Therapeutics (TSX:ATE) Headlines

No Headlines